ML-CFD-DEM based reduced order models (ROM) to quantify variability in inhalers, drugs, and users for evaluating comparability of generic oidp complex products
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01FD008379
- Recipient
-
Oklahoma State University UEI NNYDFK5FTSX9
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,001,026
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding agency
- Center for Drug Evaluation and Research Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Oklahoma City, OK, USA
Award details come from USAspending.gov.
Description
- Abstract
- Ensuring accurate predictions of the transport and deposition of orally inhaled drug products (oidps) within dry powder inhaler (DPI) flow channels to the human respiratory system is crucial. This is particularly important given the diverse variabilities such as inhaler design, drug formulation, and user-specific factors (e.g., disease-specific lung conditions and patient-device coordination). Such accuracy is essential for demonstrating comparability and bioequivalence (be) between generic and reference listed drug (RLD) inhalers, quantifying their performances' uncertainties. Although cfpd models and discrete element method (DEM) can provide high- fidelity spatiotemporal distributions of variables of interest (i.e., emitted apsds, emitted doses, regional lung deposition fractions) using 3D physiologically realistic human airway geometries, there is a drawback due to the high computational cost for using such models to investigate how numerous user-specific factors can influence the comparability and be. To address such a drawback, the overall goal of this project is to develop advanced CFD-DEM trained machine learning (ML) models, i.e., AI-empowered reduced order models (roms), to improve the understanding of variability in generic oidps, enhance comparability, and demonstrate be more efficiently. Our central approach is based on the state-of-the-art CFD-DEM, elastic airway model, and self- supervised learning (SSL), ensuring a significant contribution to accurately assessing generic inhaler comparability and performance with the reliable fast-running roms as new open-source in silico tool. Limited by the 2-year time period, the research will pursue three specific aims focusing on inhaled tiotropium bromide laden lactose particles emitted from spirivatm handihalertm based dpis in human respiratory systems with different copd severities: (1) aim 1: quantify variability of inhaler geometric design, drug formulation, and user- inhaler coordination on emitted apsds and doses from dpis using CFD-DEM and develop an AI-empowered ROM to predict emitted apsds and doses, (2) aim 2: quantify variability of copd severity on transport and deposition of inhaled oidps in the human respiratory system, and develop another ROM to predict regional lung deposition, and (3) aim 3: integrate the two roms into an "all-in-one" ROM for uncertainty quantification. In both years, we will prepare and submit CO-authored manuscripts with FDA OGD, transfer data and codes with other deliverables, and provide technical training and tutorials to them on using and further refining the roms. The proposed research is significant because the proposed roms will address the computational challenges of current CFD-based models in uncertainty quantification of in silico inhaler comparability and be studies. The proposed research is innovative since IT will integrate the state-of-the-art CFD-DEM, elastic airway, and SSL for ROM training and testing. IT will create a paradigm shift in regulatory evaluations and advance regulatory approaches to support innovation, ultimately facilitating the development and approval of generic dpis.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $299,999 | |
| Amendment | $299,999 | |
| Amendment | $299,999 | |
| Amendment | -$299,999 | |
| Amendment | -$300,000 | |
| Amendment | -$300,000 | |
| Amendment | -$299,999 | |
| Amendment | -$299,999 | |
| Amendment | -$300,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $299,999 | |
| Amendment | $299,999 | |
| Amendment | $299,999 | |
| Amendment | $299,999 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | -$50,515 | |
| Amendment | -$50,515 | |
| Amendment | -$50,515 | |
| Amendment | -$50,515 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | $50,515 | |
| Amendment | $249,485 | |
| Original award | $249,485 |
Show all 36
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Oklahoma | $225,000 |
Quick answers
Who received award U01FD008379?
U01FD008379 was awarded to Oklahoma State University by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 1, 2024.
How much is award U01FD008379 worth?
$1,001,026 has been obligated on U01FD008379.
Which agency awarded U01FD008379?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U01FD008379, with funding from Center for Drug Evaluation and Research (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award